Form 4: Revance Therapeutics CFO Tobin Schilke Reports Stock Award Vesting

CFO of Revance Therapeutics, Tobin Schilke, reports the vesting of performance-based restricted stock units (PSUs) on February 29, 2024, resulting in the acquisition of 17,447 shares of common stock.

Summary

• Tobin Schilke, CFO of Revance Therapeutics, filed a Form 4 on March 4, 2024, reporting changes in beneficial ownership of the company's stock.
• On February 29, 2024, 17,447 shares of common stock were acquired due to the vesting of performance-based restricted stock units (PSUs).
• These PSUs were granted on January 31, 2023, and vest over a three-year period based on the achievement of revenue goals.
• The Issuer's Compensation Committee certified a portion of the PSUs eligible to vest based on the achievement of a revenue goal, measured from January 1, 2023, through December 31, 2023.
• The vesting is subject to the Reporting Person remaining in continuous service through the vesting date of March 15, 2024.
• Following the reported transaction, Schilke beneficially owns 205,849 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of PSUs suggests the company is meeting its revenue goals, which is a positive indicator. However, it's a routine filing and doesn't contain significant new information.

Positives

• The vesting of PSUs indicates that Revance Therapeutics achieved certain revenue goals, as certified by the Compensation Committee.
• Tobin Schilke's continued service through the vesting date of March 15, 2024, suggests stability in the company's leadership.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of PSUs suggests continued focus on achieving revenue targets.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. The vesting of PSUs is a common form of executive compensation tied to company performance.

Comparison to Industry Standards

• Executive compensation packages often include performance-based equity awards like PSUs to align management's interests with those of shareholders.
• The specific revenue goals and vesting schedules vary widely across companies and industries, making direct comparisons difficult without more detailed information.

Stakeholder Impact

• Shareholders may view the vesting of PSUs as a positive sign, indicating that the company is achieving its revenue targets.
• Employees may be motivated by the achievement of revenue goals and the potential for future PSU vesting.

Key Dates

Keywords

Revance Therapeutics, RVNC, Tobin Schilke, CFO, Form 4, Beneficial Ownership, Performance-Based Restricted Stock Units, PSUs, Stock Vesting, Revenue Goals, Compensation Committee